India
Rheumatology · 4 min read

Spondylodysplastic Ehlers-Danlos syndrome

Learn about Spondylodysplastic Ehlers-Danlos syndrome, its reported features, relevant specialists, and questions to discuss at a medical consultation.

Also known as: Spondylodysplastic EDS; spEDS

Compiled from public sources
Text selected and arranged from Orphanet. It describes the condition as those sources do; it has not been rewritten for India.
01 Oct 2026
Not medically reviewed
No registered doctor has reviewed this page. Use it to decide who to see and what to ask — not to diagnose or treat.
—
This is not medical advice. If symptoms are severe, sudden or getting worse, call 112 (or 108 for an ambulance) or go to the nearest emergency department.

The sources compiled here do not cover: diagnosis, treatment, prevention. Ask the treating doctor about these.

What it is

From: Orphanet

A rare connective tissue disorder for which three subtypes exist, either related to the gene B4GALT7, B3GALT6 or SLC39A13, and for which the clinically overlapping characteristics include short stature (progressive in childhood), small joint hypermobility, skin hyperextensibility with soft, doughy skin especially on the hands and feet muscular hypotonia (ranging from congenitally severe to mild with later_onset), skeletal anomalies and, more variably, osteopenia, delayed motor development and bowing of the limbs. Gene-specific features, with variable presentation, are additionally observed in each subtype.

Reported clinical features and what the terms mean

The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.

The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.

Generalized joint hypermobility · Very frequent (99-80%)
Joint hypermobility (ability of a joint to move beyond its normal range of motion) affecting many or all joints of the body. In individuals with Joint hypermobility at multiple sites (usually five or more), the term generalized joint hypermobility is preferred.
Kyphoscoliosis · Very frequent (99-80%)
An abnormal curvature of the spine in both a coronal (lateral) and sagittal (back-to-front) plane.
Abnormal facial shape · Frequent (79-30%)
An abnormal morphology (form) of the face or its components.
Abnormal vertebral morphology · Frequent (79-30%)
An abnormality of one or more of the vertebrae.
Abnormality of finger · Frequent (79-30%)
An anomaly of a finger.
Abnormality of the dentition · Frequent (79-30%)
Any abnormality of the teeth.
Blue sclerae · Frequent (79-30%)
An abnormal bluish coloration of the sclera.
Flat face · Frequent (79-30%)
Absence of concavity or convexity of the face when viewed in profile.
Flexion contracture · Frequent (79-30%)
A flexion contracture is a bent (flexed) joint that cannot be straightened actively or passively. It is thus a chronic loss of joint motion due to structural changes in muscle, tendons, ligaments, or skin that prevents normal movement of joints.
Frontal bossing · Frequent (79-30%)
Bilateral bulging of the lateral frontal bone prominences with relative sparing of the midline.
Global developmental delay · Frequent (79-30%)
A delay in the achievement of motor or mental milestones in the domains of development of a child, including motor skills, speech and language, cognitive skills, and social and emotional skills. This term should only be used to describe children younger than five years of age.
Hip dysplasia · Frequent (79-30%)
The presence of developmental dysplasia of the hip.
Hyperextensible skin · Frequent (79-30%)
A condition in which the skin can be stretched beyond normal, and then returns to its initial position.
Hypertelorism · Frequent (79-30%)
Interpupillary distance more than 2 SD above the mean (alternatively, the appearance of an increased interpupillary distance or widely spaced eyes).

Other findings in the same source

From: Orphanet

Additional reported features include Hypoplastic ilia (Frequent (79-30%)); Hypotonia (Frequent (79-30%)); Increased susceptibility to fractures (Frequent (79-30%)); Joint dislocation (Frequent (79-30%)); Joint hypermobility (Frequent (79-30%)); Low-set ears (Frequent (79-30%)); Osteopenia (Frequent (79-30%)); Pes planus (Frequent (79-30%)); Platyspondyly (Frequent (79-30%)); Posteriorly rotated ears (Frequent (79-30%)). This is a selected summary, not a complete description of the condition.

When it may begin

From: Orphanet

Infancy; Neonatal

Frequency and the population described

From: Orphanet

Point prevalence: <1 / 1 000 000; Worldwide; Class only. Reported family(ies): 24.0; Worldwide. This is a published case count, not prevalence.

Which doctor should you see?

The suggested department for discussing Spondylodysplastic Ehlers-Danlos syndrome is Rheumatology, with a rheumatologist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.

This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.

How to prepare for an assessment

Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.

Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.

  • Are the findings inflammatory, structural or due to another mechanism?
  • Is there evidence that other organs need assessment?
  • How will function and any treatment-related risks be monitored?

Treatment discussions and follow-up

The material gathered for this draft does not provide a complete condition-specific treatment pathway for Spondylodysplastic Ehlers-Danlos syndrome. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.

Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.

The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.

When to seek emergency help

Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.

Find a doctor for Spondylodysplastic Ehlers-Danlos syndrome

This condition is usually assessed by a rheumatologist. Every profile shows the doctor’s registration and what has been checked.

All rheumatology conditions →

Sources

Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.

General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-2216.